Gardalsil

New research found that a single dose of the bivalent human papillomavirus (HPV) vaccine (Cervarix) may offer a similar level of protection against the serotypes of HPV types 16 and 18, which cause 70 percent of cervical cancers as the current two and three dose schedules. The findings come from a new analysis of two large phase